Theranostics Fellowship

Thank you for your interest in our new Theranostics program. We are now accepting applications for one fellowship position to begin on July 1, 2025. Please continue reading for more information.

Our Theranostics fellowship provides broad exposure to oncologic nuclear medicine with a focus on radiopharmaceutical therapies and theranostics in the treatment of oncology patients and the role of nuclear medicine diagnostic and PET/CT studies in the diagnosis and management of oncology patients, including integration of PET/CT information with information from other imaging modalities.

The Fred Hutch Cancer Center provides a robust environment for such training. Fred Hutch is designated as the SNMMI Comprehensive Radiopharmaceutical Therapy Center of Excellence, the only center in the state of Washington. The Theranostics service is rapidly growing at Fred Hutch and involves a large volume of various radiopharmaceuticals in different malignancies, including treatment of thyroid cancer with 131I, neuroendocrine tumors with 177Lu-DOTATATE and prostate cancer with 177Lu-PSMA-617 and 223Ra dichloride. In 2025 a fully equipped dedicated Theranostics unit with 8 treatment bays will expand the capacity for radiopharmaceutical therapies.  

Quantitative post-treatment SPECT/CT is performed after each radiopharmaceutical treatment administration on GE 870 SPECT/CT scanner and an additional state-of-the-art multi-detector SPECT/CT camera will be installed in 2025 to expand the center’s capacity.   

The center is equipped with a PET/CT scanner (GE Discovery MI) and a PET/MRI scanner (one of the first United Imaging PET/MRI scanners installed in the US). Various standard-of-care oncologic PET studies are performed daily on both scanners utilizing various radiotracers including 18F-FDG, 68Ga-PSMA, 18F-PSMA, 68Ga- Dotatate, 64Cu-Dotatate and 18F-FES.  PET imaging capacity is planned to increase significantly in 2025-2026 with an additional extended field of view PET/CT camera.   

The center also leads and supports several clinical research studies using novel diagnostic and therapeutic radiopharmaceuticals.  The center can perform various clinical trials including phase 0/first in-human and phase 3 trials and the Theranostics fellow is expected to be actively involved in the conduct of these trials.  

 Fellows who complete this fellowship training course will have expertise in the following areas:

• Patient evaluation and safe administration of nuclear medicine therapies, with detailed knowledge of clinical workflows such that they will be equipped to start new clinical services or contribute to optimized workflows of existing clinical nuclear medicine therapy services.
• Clinical applications and interpretations of standard clinical and novel molecular imaging tests.
• Clinical research study design approaches, image interpretation, and data analysis.
• Contributing nuclear medicine expertise to multidisciplinary discussions.